Medicine in China

Q&A: Transcenta sees promising future in biologics

The biopharmaceutical startup backed by Lilly Asia Ventures, Temasek and Sequoia China is looking both at its next round of funding and at an IPO next year.

Over the past five years, biotech investment has experienced the fastest development in China. Pharmaceutical companies have become a rising force that has attracted increasing amount of capital.  

¬ Haymarket Media Limited. All rights reserved.

Sign in to read on!

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

Share our publication on social media
Share our publication on social media